Citations (83)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (20)
T. D. Filippatos, M. Florentin, M. Georgoula & M. S. Elisaf. (2017) Pharmacological management of diabetic dyslipidemia. Expert Review of Clinical Pharmacology 10:2, pages 187-200.
Read now
Read now
Anastazia A. Kei, Theodosios D. Filippatos & Moses S. Elisaf. (2016) The safety of ezetimibe and simvastatin combination for the treatment of hypercholesterolemia. Expert Opinion on Drug Safety 15:4, pages 559-569.
Read now
Read now
TD Filippatos, CS Derdemezis, PV Voulgari, V Tsimihodimos, MS Elisaf, AD Tselepis & AA Drosos. (2013) Effects of 12 months of treatment with disease-modifying anti-rheumatic drugs on low and high density lipoprotein subclass distribution in patients with early rheumatoid arthritis: a pilot study. Scandinavian Journal of Rheumatology 42:3, pages 169-175.
Read now
Read now
Ioanna Gouni-Berthold, Dimitri P. Mikhailidis & Manfredi Rizzo. (2012) Clinical benefits of ezetimibe use: is absence of proof, proof of absence?. Expert Opinion on Pharmacotherapy 13:14, pages 1985-1988.
Read now
Read now
Michael S. Kostapanos, Vasilios G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2012) Therapeutic options for statin-intolerant patients. Current Medical Research and Opinion 28:3, pages 345-349.
Read now
Read now
Theodosios D Filippatos & Moses S Elisaf. (2011) Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opinion on Pharmacotherapy 12:12, pages 1945-1958.
Read now
Read now
Matilda Florentin, Evangelos N Liberopoulos, Dimitri P Mikhailidis & Moses S Elisaf. (2011) Emerging options in the treatment of dyslipidemias: a bright future?. Expert Opinion on Emerging Drugs 16:2, pages 247-270.
Read now
Read now
Niki Katsiki, Vasilis G. Athyros, Asterios Karagiannis & Dimitri P. Mikhailidis. (2011) Ezetimibe and low density lipoprotein subfractions: an ongoing debate. Current Medical Research and Opinion 27:3, pages 693-695.
Read now
Read now
Matilda Florentin, Evangelos N. Liberopoulos, Elisavet Moutzouri, Christos V. Rizos, Alexandros D. Tselepis & Moses S. Elisaf. (2011) The effect of simvastatin alone versus simvastatin plus ezetimibe on the concentration of small dense low-density lipoprotein cholesterol in subjects with primary hypercholesterolemia. Current Medical Research and Opinion 27:3, pages 685-692.
Read now
Read now
Maria Sarigianni, Niki Katsiki & Dimitri P Mikhailidis. (2010) Ezetimibe in diabetes: more than cholesterol lowering?. Current Medical Research and Opinion 26:10, pages 2517-2520.
Read now
Read now
Fabrizio Montecucco, Alessandra Quercioli & François Mach. (2009) Ezetimibe/simvastatin. Expert Opinion on Drug Safety 8:6, pages 715-725.
Read now
Read now
ES Nakou, TD Filippatos, DN Kiortsis, CS Derdemezis, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia. Expert Opinion on Pharmacotherapy 9:18, pages 3151-3158.
Read now
Read now
Zlatko Fras & Dimitri P Mikhailidis. (2008) Statin plus ezetimibe treatment in clinical practice: the SI-SPECT (Slovenia (SI) Statin Plus Ezetimibe in Cholesterol Treatment) monitoring of clinical practice study. Current Medical Research and Opinion 24:9, pages 2467-2476.
Read now
Read now
CS Derdemezis, TD Filippatos, AD Tselepis, DP Mikhailidis & MS Elisaf. (2008) Effects of ezetimibe, either alone or in combination with atorvastatin, on serum visfatin levels: a pilot study. Expert Opinion on Pharmacotherapy 9:11, pages 1829-1837.
Read now
Read now
E. S. Nakou, T. D. Filippatos, M. Georgoula, D. N. Kiortsis, A. D. Tselepis, D. P. Mikhailidis & M. S. Elisaf. (2008) The effect of orlistat and ezetimibe, alone or in combination, on serum LDL and small dense LDL cholesterol levels in overweight and obese patients with hypercholesterolaemia. Current Medical Research and Opinion 24:7, pages 1919-1929.
Read now
Read now
Harold E Bays, David Neff, Joanne E Tomassini & Andrew M Tershakovec. (2008) Ezetimibe: cholesterol lowering and beyond. Expert Review of Cardiovascular Therapy 6:4, pages 447-470.
Read now
Read now
M. Florentin, E. N. Liberopoulos, D. P. Mikhailidis & M. S. Elisaf. (2008) Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Current Medical Research and Opinion 24:4, pages 995-1009.
Read now
Read now
Henk W. O. Roeters van Lennep, An Ho Liem, Peter H. J. M. Dunselman, Geesje M. Dallinga-Thie, Aeilko H. Zwinderman & J. Wouter Jukema. (2008) The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study. Current Medical Research and Opinion 24:3, pages 685-694.
Read now
Read now
Dimitri P Mikhailidis & Martin Press. (2007) The importance of treating multiple cardiometabolic risk factors in patients with Type 2 diabetes. Expert Opinion on Pharmacotherapy 8:17, pages 3009-3020.
Read now
Read now
Irene F. Gazi, Stella S. Daskalopoulou, Devaki R. Nair & Dimitri P. Mikhailidis. (2007) Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Current Medical Research and Opinion 23:9, pages 2183-2192.
Read now
Read now
Articles from other publishers (63)
Panagiotis Anagnostis, Vasileios Kotsis, Maciej Banach & Dimitri P. Mikhailidis. (2023) Could Lowering Phytosterol Absorption as Part of Lipid-Lowering Therapy Have a Beneficial Effect on Residual Risk?. Metabolites 13:2, pages 145.
Crossref
Crossref
Zlatko Fras & Dimitri P. Mikhailidis. (2021) Have We Learnt all from IMPROVE-IT? Part I. Core Results and Subanalyses on the Effects of Ezetimibe Added to Statin Therapy Related to Age, Gender and Selected Chronic Diseases (Kidney Disease, Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease). Current Vascular Pharmacology 19:5, pages 451-468.
Crossref
Crossref
A. V. Blokhina, A. I. Ershova, A. N. Meshkov, A. S. Limonova, V. I. Mikhailina & O. M. Drapkina. (2021) Lipid Clinic is an Efficacious Model of Preventive Medicine. Rational Pharmacotherapy in Cardiology 17:1, pages 4-10.
Crossref
Crossref
Peiyang Zhou, Jincheng Liu, Lingyun Wang, Wenmin Feng, Zhihua Cao, Pu Wang, Guangzhi Liu, Chenglin Sun, Yan Shen, Lijun Wang, Jiahuan Xu, Peng Meng, Ziwei Li, Wang-yang Xu & Xifa Lan. (2020) Association of Small Dense Low-Density Lipoprotein Cholesterol with Stroke Risk, Severity and Prognosis. Journal of Atherosclerosis and Thrombosis 27:12, pages 1310-1324.
Crossref
Crossref
Cécile Ingueneau, Tim Hollstein, Thomas Grenkowitz, Jean-Bernard Ruidavets, Ursula Kassner, Thibaut Duparc, Guillaume Combes, Bertrand Perret, Annelise Genoux, Friederike Schumann, Thomas Bobbert, Elisabeth Steinhagen-Thiessen & Laurent O. Martinez. (2020) Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk. Vascular Pharmacology 135, pages 106804.
Crossref
Crossref
Shahin Alizadeh-Fanalou, Ali Nazarizadeh, Fatemeh Alian, Parisa Faraji, Bahareh Sorori & Mohsen Khosravi. (2020) Small dense low-density lipoprotein-lowering agents. Biological Chemistry 401:10, pages 1101-1121.
Crossref
Crossref
Bingli Zhao, Yujiao Cui, Xiaodan Fan, Ping Qi, Chunchen Liu, Xuesong Zhou & Xuewu Zhang. (2019) Anti-obesity effects of Spirulina platensis protein hydrolysate by modulating brain-liver axis in high-fat diet fed mice. PLOS ONE 14:6, pages e0218543.
Crossref
Crossref
Theodosios D. Filippatos, Angelos Liontos, Eliza C. Christopoulou & Moses S. Elisaf. (2019) Novel Hypolipidaemic Drugs: Mechanisms of Action and Main Metabolic Effects. Current Vascular Pharmacology 17:4, pages 332-340.
Crossref
Crossref
Niki Katsiki & Dimitri P Mikhailidis. (2018) Lipids: a personal view of the past decade. Hormones 17:4, pages 461-478.
Crossref
Crossref
Theodosios D. Filippatos, Anastazia Kei, Christos V. Rizos & Moses S. Elisaf. (2017) Effects of PCSK9 Inhibitors on Other than Low-Density Lipoprotein Cholesterol Lipid Variables. Journal of Cardiovascular Pharmacology and Therapeutics 23:1, pages 3-12.
Crossref
Crossref
Rgia A. Othman, Semone B. Myrie, David Mymin, Jean-Baptiste Roullet, Robert D. Steiner & Peter J.H. Jones. (2017) Effect of ezetimibe on low- and high-density lipoprotein subclasses in sitosterolemia. Atherosclerosis 260, pages 27-33.
Crossref
Crossref
Jun-beom Lee, Gyeong-Seon Kim & Han-na Cho. (2017) Statin and Ezetimibe Combination Therapy Decreases Mean Platelet Volume Compared to Statin Monotherapy. Journal of Stroke 19:1, pages 109-110.
Crossref
Crossref
Theodosios D. Filippatos & Moses S. Elisaf. (2015) Statin–Ezetimibe Combination Therapy In Diabetic Individuals. Angiology 67:6, pages 507-509.
Crossref
Crossref
Antonio Eduardo P. Pesaro, Christopher B. Granger & Renato D. Lopes. (2016) Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?. American Heart Journal 172, pages 42-44.
Crossref
Crossref
Enrique Galve, Carlos Guijarro-Herraiz, Luis Masana-Marin & Alberto Cordero-Fort. (2016) Consenso sobre los objetivos y pautas de actuación en el control del colesterol ligado a lipoproteínas de baja densidad en pacientes de muy alto riesgo cardiovascular. Clínica e Investigación en Arteriosclerosis 28:1, pages 31-42.
Crossref
Crossref
Jeffrey B. Rosen, Christie M. Ballantyne, Willa A. Hsueh, Jianxin Lin, Arvind K. Shah, Robert S. Lowe & Andrew M. Tershakovec. (2015) Influence of metabolic syndrome factors and insulin resistance on the efficacy of ezetimibe/simvastatin and atorvastatin in patients with metabolic syndrome and atherosclerotic coronary heart disease risk. Lipids in Health and Disease 14:1.
Crossref
Crossref
L. Nibali, M. Rizzo, G. Li Volti, F. D'Aiuto, R. V. Giglio, I. Barbagallo, G. Pelekos & N. Donos. (2015) Lipid subclasses profiles and oxidative stress in aggressive periodontitis before and after treatment. Journal of Periodontal Research 50:6, pages 890-896.
Crossref
Crossref
Ryuji Kato, Satoshi Nishioka, Atsuo Nomura, Yoshio Ijiri, Masatoshi Miyamura, Akira Ukimura, Yoshikatsu Okada, Yasushi Kitaura & Tetsuya Hayashi. (2015) Cardiovascular protection by ezetimibe and influence on oxidative stress in mice exposed to intermittent hypoxia. European Journal of Pharmacology 765, pages 7-14.
Crossref
Crossref
Wojciech Fendler, Manfredi Rizzo, Maciej Borowiec, Beata Malachowska, Karolina Antosik, Agnieszka Szadkowska, Maciej Banach, Malgorzata Urbanska-Kosinska, Magdalena Szopa, Maciej Malecki & Wojciech Mlynarski. (2014) Less but better: cardioprotective lipid profile of patients with GCK-MODY despite lower HDL cholesterol level. Acta Diabetologica 51:4, pages 625-632.
Crossref
Crossref
Manfredi Rizzo, Rosaria Vincenza Giglio, Dragana Nikolic, Angelo Maria Patti, Claudia Campanella, Massimo Cocchi, Niki Katsiki & Giuseppe Montalto. (2013) Effects of Chitosan on Plasma Lipids and Lipoproteins. Angiology 65:6, pages 538-542.
Crossref
Crossref
Noriko Oza, Hirokazu Takahashi, Yuichiro Eguchi, Yoichiro Kitajima, Takuya Kuwashiro, Eriko Ishibashi, Shunya Nakashita, Shinji Iwane, Yasunori Kawaguchi, Toshihiko Mizuta, Iwata Ozaki, Naofumi Ono, Takahisa Eguchi, Kazuma Fujimoto & Keizo Anzai. (2014) Efficacy of ezetimibe for reducing serum low-density lipoprotein cholesterol levels resistant to lifestyle intervention in patients with non-alcoholic fatty liver disease. Hepatology Research 44:7, pages 812-817.
Crossref
Crossref
Heiner K. Berthold, Manfredi Rizzo, Nadine Spenrath, Giuseppe Montalto, Wilhelm Krone & Ioanna Gouni-Berthold. (2014) Effects of Lipid-Lowering Drugs on High-Density Lipoprotein Subclasses in Healthy Men—A Randomized Trial. PLoS ONE 9:3, pages e91565.
Crossref
Crossref
Nicola Scichilone, Manfredi Rizzo, Alida Benfante, Roberta Catania, Rosaria Vincenza Giglio, Dragana Nikolic, Giuseppe Montalto & Vincenzo Bellia. (2013) Serum low density lipoprotein subclasses in asthma. Respiratory Medicine 107:12, pages 1866-1872.
Crossref
Crossref
Naoko Kumagai, Shin-ichiro Miura, Bo Zhang, Keita Noda & Keijiro Saku. (2013) Effects of ezetimibe on hypercholesterolemia in the lipid profile in patients with metabolic syndrome: Zenith Trial. IJC Metabolic & Endocrine 1, pages 7-12.
Crossref
Crossref
Ngoc‐Anh Le, Ran Jin, Joanne E. Tomassini, Andrew M. Tershakovec, David R. Neff & Peter W.F. Wilson. (2013) Changes in Lipoprotein Particle Number With Ezetimibe/Simvastatin Coadministered With Extended‐Release Niacin in Hyperlipidemic Patients. Journal of the American Heart Association 2:4.
Crossref
Crossref
Jun Kido, Kimitoshi Nakamura, Shirou Matsumoto, Hiroshi Mitsubuchi, Toshihiro Ohura, Yosuke Shigematsu, Tohru Yorifuji, Mureo Kasahara, Reiko Horikawa & Fumio Endo. (2013) Current status of hepatic glycogen storage disease in Japan: clinical manifestations, treatments and long-term outcomes. Journal of Human Genetics 58:5, pages 285-292.
Crossref
Crossref
Dragana Nikolic, Niki Katsiki, Giuseppe Montalto, Esma Isenovic, Dimitri Mikhailidis & Manfredi Rizzo. (2013) Lipoprotein Subfractions in Metabolic Syndrome and Obesity: Clinical Significance and Therapeutic Approaches. Nutrients 5:3, pages 928-948.
Crossref
Crossref
Michael S. Kostapanos, Moses S. Elisaf & Dimitri P. Mikhailidis. (2012) Effect of Atorvastatin Monotherapy and Low-Dose Atorvastatin/Ezetimibe Combination on Fasting and Postprandial Triglycerides in Combined Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 17:4, pages 427-427.
Crossref
Crossref
Michael S Kostapanos, Dimitri P Mikhailidis & Moses S Elisaf. (2012) Adding ezetimibe to statin treatment: is LDL-C lowering the only benefit?. Future Cardiology 8:6, pages 813-817.
Crossref
Crossref
Antonio Hernández-Mijares, Celia Bañuls, Lorena Bellod, Ana Jover, Eva Solá, Víctor M. Víctor & Milagros Rocha. (2012) Estudio de las subfracciones lipoproteicas tras el tratamiento de simvastatina y ezetimiba, en monoterapia o combinado, en pacientes hiperlipidémicos. Clínica e Investigación en Arteriosclerosis 24:5, pages 217-225.
Crossref
Crossref
Anastazia A. Kei, Theodosios D. Filippatos, Vasilios Tsimihodimos & Moses S. Elisaf. (2012) A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease. Metabolism 61:7, pages 906-921.
Crossref
Crossref
Michael S. Kostapanos, Moses S. Elisaf & Dimitri P. Mikhailidis. (2012) Ezetimibe – a new approach in hypercholesterolemia management. Pharmacological Reports 64:4, pages 997-998.
Crossref
Crossref
Theodosios D. Filippatos. (2012) A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination. Cardiovascular Drugs and Therapy 26:3, pages 245-255.
Crossref
Crossref
Yukinori Tamura, Toshinori Murayama, Manabu Minami, Takeshi Matsubara, Masayuki Yokode & Hidenori Arai. (2012) Ezetimibe Ameliorates Early Diabetic Nephropathy in db/db Mice. Journal of Atherosclerosis and Thrombosis 19:7, pages 608-618.
Crossref
Crossref
Noboru Tamaki, Hiroaki Ueno, Yuta Morinaga, Tomomi Shiiya & Masamitsu Nakazato. (2012) Ezetimibe Ameliorates Atherosclerotic and Inflammatory Markers, Atherogenic Lipid Profiles, Insulin Sensitivity, and Liver Dysfunction in Japanese Patients with Hypercholesterolemia. Journal of Atherosclerosis and Thrombosis 19:6, pages 532-538.
Crossref
Crossref
Kokoro Tsuzaki, Kazuhiko Kotani, Yoshiko Sano, Shinji Fujiwara, Irene F. Gazi, Moses Elisaf & Naoki Sakane. (2012) The relationship between adiponectin, an adiponectin gene polymorphism, and high-density lipoprotein particle size: from the Mima study. Metabolism 61:1, pages 17-21.
Crossref
Crossref
Karl Winkler, Stephan Jacob, Tina Müller-Schewe, Michael M. Hoffmann & Thomas Konrad. (2012) Ezetimibe alone and in combination lowers the concentration of small, dense low-density lipoproteins in type 2 diabetes mellitus. Atherosclerosis 220:1, pages 189-193.
Crossref
Crossref
Kosmas I. ParaskevasAlkistis Pantopoulou, Ioannis S. Vlachos, George Agrogiannis, Dimitrios G. Iliopoulos, Gabriel Karatzas, Dimitrios Tzivras, Dimitri P. Mikhailidis & Despina N. Perrea. (2011) Comparison of Fibrate, Ezetimibe, Low- and High-Dose Statin Therapy for the Dyslipidemia of the Metabolic Syndrome in a Mouse Model. Angiology 62:2, pages 144-154.
Crossref
Crossref
K. Berneis, M. Rizzo, H. K. Berthold, G. A. Spinas, W. Krone & I. Gouni-Berthold. (2010) Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. European Heart Journal 31:13, pages 1633-1639.
Crossref
Crossref
Rabih R. Azar, Georges Badaoui, Antoine Sarkis, Mireille Azar, Herminé Aydanian, Serge Harb, Guy Achkouty & Roland Kassab. (2010) Effect of Ezetimibe/Atorvastatin Combination on Oxidized Low Density Lipoprotein Cholesterol in Patients With Coronary Artery Disease or Coronary Artery Disease Equivalent. The American Journal of Cardiology 106:2, pages 193-197.
Crossref
Crossref
Ae-Young Her, Jong-Youn Kim, Seok-Min Kang, Donghoon Choi, Yangsoo Jang, Namsik Chung, Ichiro Manabe & Sang-Hak Lee. (2010) Effects of Atorvastatin 20 mg, Rosuvastatin 10 mg, and Atorvastatin/Ezetimibe 5 mg/5 mg on Lipoproteins and Glucose Metabolism. Journal of Cardiovascular Pharmacology and Therapeutics 15:2, pages 167-174.
Crossref
Crossref
Christos S. Derdemezis, Theodosios D. Filippatos, Dimitri P. Mikhailidis & Moses S. Elisaf. (2010) Review Article: Effects of Plant Sterols and Stanols Beyond Low-Density Lipoprotein Cholesterol Lowering. Journal of Cardiovascular Pharmacology and Therapeutics 15:2, pages 120-134.
Crossref
Crossref
Matilda Florentin, Evangelos N. Liberopoulos, Costas C. Tellis, Christos S. Derdemezis, Moses Elisaf & Alexandros Tselepis. (2009) Effects of Rimonabant, as Monotherapy and in Combination With Fenofibrate or Ezetimibe, on Plasma Adipokine Levels: A Pilot Study. Angiology 61:4, pages 365-371.
Crossref
Crossref
Juan F. Ascaso. (2010) Avances en el tratamiento de la hipercolesterolemia. Endocrinología y Nutrición 57:5, pages 210-219.
Crossref
Crossref
Michalis Kalogirou, Vasilis Tsimihodimos & Moses Elisaf. (2010) Pleiotropic effects of ezetimibe: Do they really exist?. European Journal of Pharmacology 633:1-3, pages 62-70.
Crossref
Crossref
E. S. Nakou, T. D. Filippatos, A. P. Agouridis, C. Kostara, E. T. Bairaktari & M. S. Elisaf. (2010) The Effects of Ezetimibe and/or Orlistat on Triglyceride-Rich Lipoprotein Metabolism in Obese Hypercholesterolemic Patients. Lipids 45:5, pages 445-450.
Crossref
Crossref
Yasunori Sawayama, Shinji Maeda, Hachiro Ohnishi, Shin Hayashi & Jun Hayashi. (2010) Efficacy and Safety of Ezetimibe for Japanese Patients with Dyslipidaemia. Clinical Drug Investigation 30:3, pages 157-166.
Crossref
Crossref
T. Stojakovic, A. De Campo, H. Scharnagl, H. Sourij, I. Schmölzer, T. C. Wascher & W. März. (2010) Differential effects of fluvastatin alone or in combination with ezetimibe on lipoprotein subfractions in patients at high risk of coronary events. European Journal of Clinical Investigation 40:3, pages 187-194.
Crossref
Crossref
Vasilis Tsimihodimos, Irene Gazi, Theodosios Filippatos, Michael Kostapanos, Kostantinos Lagos, Christina Kostara, Constantinos C. Tellis, Moses Elisaf & Alexandros D. Tselepis. (2010) Plasma triglyceride levels and body mass index values are the most important determinants of preβ-1 HDL concentrations in patients with various types of primary dyslipidemia. Atherosclerosis 208:2, pages 506-511.
Crossref
Crossref
Tsuyoshi Nozue, Ichiro Michishita & Ichiro Mizuguchi. (2010) Effects of Ezetimibe on Remnant-Like Particle Cholesterol, Lipoprotein (a), and Oxidized Low-Density Lipoprotein in Patients with Dyslipidemia. Journal of Atherosclerosis and Thrombosis 17:1, pages 37-44.
Crossref
Crossref
Toshikazu Araoka, Hiroya Takeoka, Hideharu Abe, Seiji Kishi, Makoto Araki, Keisuke Nishioka, Masaki Ikeda, Tetsuro Mazaki, Shiori Ikemura, Makiko Kondo, Azusa Hoshina, Kojiro Nagai, Akira Mima, Taichi Murakami, Rokuro Mimura, Kazumasa Oka, Takao Saito & Toshio Doi. (2010) Early Diagnosis and Treatment may Prevent the Development of Complications in an Adult Patient with Glycogen Storage Disease Type .IOTA.a. Internal Medicine 49:16, pages 1787-1792.
Crossref
Crossref
Kenta Okada, Hiroaki Yagyu, Kazuhiko Kotani, Michiaki Miyamoto, Jun-ichi Osuga, Shoichiro Nagasaka & Shun Ishibashi. (2010) Lipid-lowering effects of ezetimibe for hypercholesterolemic patients with and without type 2 diabetes mellitus. Endocrine Journal 57:10, pages 903-908.
Crossref
Crossref
Matilda Florentin, Michael S. Kostapanos, Eleni S. Nakou, Moses ElisafEvangelos N. Liberopoulos. (2009) Efficacy and Safety of Ezetimibe Plus Orlistat or Rimonabant in Statin-Intolerant Nondiabetic Overweight/Obese Patients With Dyslipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 14:4, pages 274-282.
Crossref
Crossref
Manfredi Rizzo, Giovam Battista Rini, Giatgen A. Spinas & Kaspar Berneis. (2009) The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?. Atherosclerosis 204:2, pages 330-333.
Crossref
Crossref
Michael S. Kostapanos, Haralampos J. Milionis, Theodosios D. Filippatos, Leonidas G. Christogiannis, Eleni T. Bairaktari, Alexandros D. Tselepis & Moses S. Elisaf. (2009) Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia. Journal of Cardiovascular Pharmacology and Therapeutics 14:1, pages 5-13.
Crossref
Crossref
Michel Farnier. (2010) Pharmacotherapy of Mixed Hyperlipidemia with Ezetimibe-Fenofibrate Combination Therapy. Clinical Medicine. Therapeutics 1, pages CMT.S2036.
Crossref
Crossref
Shin-ichiro Miura & Keijiro Saku. (2008) Beneficial effects of ezetimibe-based therapy in patients with dyslipidemia. Journal of Cardiology 52:1, pages 1-6.
Crossref
Crossref
Michael S. Kostapanos, Haralampos J. Milionis, Konstantinos G. Lagos, Christos B. Rizos, Alexandros D. Tselepis & Moses S. Elisaf. (2008) Baseline triglyceride levels and insulin sensitivity are major determinants of the increase of LDL particle size and buoyancy induced by rosuvastatin treatment in patients with primary hyperlipidemia. European Journal of Pharmacology 590:1-3, pages 327-332.
Crossref
Crossref
Osamah Hussein, LiLia Minasian, Yaroslav Itzkovich, Karina Shestatski, Lizora Solomon & Jamal Zidan. (2008) Ezetimibe's effect on platelet aggregation and LDL tendency to peroxidation in hypercholesterolaemia as monotherapy or in addition to simvastatin. British Journal of Clinical Pharmacology 65:5, pages 637-645.
Crossref
Crossref
. (2008) Current World Literature. Current Opinion in Endocrinology, Diabetes & Obesity 15:2, pages 193-219.
Crossref
Crossref
Shin-ichiro Miura & Keijiro Saku. (2008) Ezetimibe, a Selective Inhibitor of the Transport of Cholesterol. Internal Medicine 47:13, pages 1165-1170.
Crossref
Crossref
M. Florentin, E. N. Liberopoulos & M. S. Elisaf. (2007) Ezetimibe-associated adverse effects: what the clinician needs to know. International Journal of Clinical Practice 62:1, pages 88-96.
Crossref
Crossref
M. Rizzo & K. Berneis. (2007) Who needs to care about small, dense low-density lipoproteins?. International Journal of Clinical Practice 61:11, pages 1949-1956.
Crossref
Crossref